Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21.

Colleoni B, Paternot S, Pita JM, Bisteau X, Coulonval K, Davis RJ, Raspé E, Roger PP.

Oncogene. 2017 Jul 27;36(30):4349-4361. doi: 10.1038/onc.2017.7. Epub 2017 Apr 3.

2.

The Fra-1-miR-134-SDS22 feedback loop amplifies ERK/JNK signaling and reduces chemosensitivity in ovarian cancer cells.

Wu J, Sun Y, Zhang PY, Qian M, Zhang H, Chen X, Ma D, Xu Y, Chen X, Tang KF.

Cell Death Dis. 2016 Sep 29;7(9):e2384. doi: 10.1038/cddis.2016.289.

3.

JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships.

Zeke A, Misheva M, Reményi A, Bogoyevitch MA.

Microbiol Mol Biol Rev. 2016 Jul 27;80(3):793-835. doi: 10.1128/MMBR.00043-14. Print 2016 Sep. Review.

4.

Regulatory Roles of MAPK Phosphatases in Cancer.

Low HB, Zhang Y.

Immune Netw. 2016 Apr;16(2):85-98. doi: 10.4110/in.2016.16.2.85. Epub 2016 Apr 28. Review.

5.

Black Rice Anthocyanins Suppress Metastasis of Breast Cancer Cells by Targeting RAS/RAF/MAPK Pathway.

Chen XY, Zhou J, Luo LP, Han B, Li F, Chen JY, Zhu YF, Chen W, Yu XP.

Biomed Res Int. 2015;2015:414250. doi: 10.1155/2015/414250. Epub 2015 Nov 16.

6.

Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.

Marusiak AA, Stephenson NL, Baik H, Trotter EW, Li Y, Blyth K, Mason S, Chapman P, Puto LA, Read JA, Brassington C, Pollard HK, Phillips C, Green I, Overman R, Collier M, Testoni E, Miller CJ, Hunter T, Sansom OJ, Brognard J.

Cancer Res. 2016 Feb 1;76(3):724-35. doi: 10.1158/0008-5472.CAN-15-0701-T. Epub 2015 Dec 4.

7.

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.

Nonami A, Sattler M, Weisberg E, Liu Q, Zhang J, Patricelli MP, Christie AL, Saur AM, Kohl NE, Kung AL, Yoon H, Sim T, Gray NS, Griffin JD.

Blood. 2015 May 14;125(20):3133-43. doi: 10.1182/blood-2014-12-615906. Epub 2015 Apr 1.

8.

Impaired Hippo signaling promotes Rho1-JNK-dependent growth.

Ma X, Chen Y, Xu W, Wu N, Li M, Cao Y, Wu S, Li Q, Xue L.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1065-70. doi: 10.1073/pnas.1415020112. Epub 2015 Jan 12.

9.

Rsu1 contributes to cell adhesion and spreading in MCF10A cells via effects on P38 map kinase signaling.

Kim YC, Gonzalez-Nieves R, Cutler ML.

Cell Adh Migr. 2015;9(3):227-32. doi: 10.4161/19336918.2014.972775. Epub 2014 Oct 23.

10.

Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition.

Derynck R, Muthusamy BP, Saeteurn KY.

Curr Opin Cell Biol. 2014 Dec;31:56-66. doi: 10.1016/j.ceb.2014.09.001. Epub 2014 Sep 18. Review.

11.

Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation.

Okada M, Shibuya K, Sato A, Seino S, Suzuki S, Seino M, Kitanaka C.

Oncotarget. 2014 Jul 15;5(13):5100-12.

12.

Novel mechanism of JNK pathway activation by adenoviral E1A.

Romanov VS, Brichkina AI, Morrison H, Pospelova TV, Pospelov VA, Herrlich P.

Oncotarget. 2014 Apr 30;5(8):2176-86.

13.

The 2 Faces of JNK Signaling in Cancer.

Tournier C.

Genes Cancer. 2013 Sep;4(9-10):397-400. doi: 10.1177/1947601913486349. Review.

14.

JNK Signaling in the Control of the Tumor-Initiating Capacity Associated with Cancer Stem Cells.

Kitanaka C, Sato A, Okada M.

Genes Cancer. 2013 Sep;4(9-10):388-96. doi: 10.1177/1947601912474892. Review.

15.

c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade.

Ebelt ND, Cantrell MA, Van Den Berg CL.

Genes Cancer. 2013 Sep;4(9-10):378-87. doi: 10.1177/1947601913485413. Review.

16.

BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling.

Vin H, Ojeda SS, Ching G, Leung ML, Chitsazzadeh V, Dwyer DW, Adelmann CH, Restrepo M, Richards KN, Stewart LR, Du L, Ferguson SB, Chakravarti D, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Kim KB, Ciurea AM, Duvic M, Prieto VG, Ullrich SE, Dalby KN, Flores ER, Tsai KY.

Elife. 2013 Nov 5;2:e00969. doi: 10.7554/eLife.00969.

17.

FXR silencing in human colon cancer by DNA methylation and KRAS signaling.

Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, Izzo J, He N, Wei C, Baladandayuthapani V, Liang H, Kopetz S, Powis G, Guo GL.

Am J Physiol Gastrointest Liver Physiol. 2014 Jan 1;306(1):G48-58. doi: 10.1152/ajpgi.00234.2013. Epub 2013 Oct 31. Erratum in: Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G357.

18.

JNK signalling in cancer: in need of new, smarter therapeutic targets.

Bubici C, Papa S.

Br J Pharmacol. 2014 Jan;171(1):24-37. doi: 10.1111/bph.12432. Review.

19.

Combining docking site and phosphosite predictions to find new substrates: identification of smoothelin-like-2 (SMTNL2) as a c-Jun N-terminal kinase (JNK) substrate.

Gordon EA, Whisenant TC, Zeller M, Kaake RM, Gordon WM, Krotee P, Patel V, Huang L, Baldi P, Bardwell L.

Cell Signal. 2013 Dec;25(12):2518-29. doi: 10.1016/j.cellsig.2013.08.004. Epub 2013 Aug 24.

20.

Supplemental Content

Support Center